BioLineRx Releases Q2 2026 Financial Results - Alphastreet

BioLineRx and Hemispherian will present GLIX1 data at EANO 2026, showing promising preclinical results in glioblastoma models. The Phase 1/2a trial is ongoing. BLRX stock is up 9.80% in pre-market trading.

BioLineRx (BLRX) and Hemispherian AS announced preclinical data and trial design for GLIX1, a TET2 activator, will be presented at EANO 2026. GLIX1 showed anti-tumor activity in glioblastoma models, with a Phase 1/2a trial actively enrolling patients. BioLineRx is developing GLIX1 for glioblastoma and other solid tumors.

BioLineRx (BLRX) reported 2Q 2026 revenues of $294,000 and a net loss of $4.3 million. The company's GLIX1 clinical trial is progressing, with new data showing synergistic effects with a PARP inhibitor. BioLineRx raised $3.75 million in capital to support development. The trial's Phase I/IIa results are expected in 1H 2027.

BioLineRx Ltd. (BLRX) furnished an SEC Form 6-K — earnings release. Exhibit 1 For Immediate Release BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data

American Airlines reported a record revenue of $16.3bn in Q3 2026, up 19.3% YoY, but posted an adjusted net loss of $182m. Fuel expenses surged 67.5%, impacting profitability. The company expects Q4 revenue growth of 19.5-22.5% but anticipates a wider loss due to rising fuel costs. The stock rose 3.3% to $12.6.

American Airlines reported Q3 2026 revenue of $16.3B, up 19.3% YoY, but a net loss of $269M due to rising fuel costs. Premium and business travel drove revenue gains, with fuel expenses increasing $1.9B. The airline expects higher fuel prices to slow 2027 network growth and forecasts a Q4 adjusted loss of $0.50-$1.10 per share.